Animas insulin pump recall
This article was originally published in The Gray Sheet
Executive SummaryAugust recall of battery caps used in Animas OneTouch Ping, 2020, IR1200 and IR1250 insulin pump systems is Class I, the most serious category, FDA announces Nov. 20. The recalled battery caps were losing contact with the insulin pump's battery compartment, causing the pump to reset and temporarily lose power. This could cause either a loss of insulin delivery, resulting in hyperglycemia, or accidental overdosing by the user, resulting in hypoglycemia, FDA notes. Animas sent letters to customers from Aug. 18 to Sept. 1, which included replacement battery caps, and also sent letters to distributors
You may also be interested in...
The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.